ニュース
Acticor Biotech will present the clinical results of its phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024
Acticor Biotech will present the clinical results of its phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024
-
Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024
-
Presentation of results during ESOC from 15 to 17 May 2024
Paris, France, April 15, 2024 – 06:00 pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, focusing stroke, announces today its participation in the European Stroke Organization Conference (ESOC) 2024, to be held from 15 to 17 May 2024 in Basel, Switzerland.
ESOC is the leading European forum for stroke research and the preferred platform for the publication of major clinical trial data.
At this conference, the Company will present the results of its phase 2/3 ACTISAVE study, which is evaluating glenzocimab in the treatment of stroke: “ACTISAVE Clinical Trial: Efficacy and Satefy of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy” - Abstract N°357 - Presentation by Pr. Martin Köhrmann.
As a reminder, ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke. Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy.
Sophie BINAY, Chief Operating Officer and Chief Scientific Officer, stated: "We are looking forward to the results of our phase 2/3 clinical trial ACTISAVE in stroke, which we expect to be available in the next few weeks and which will represent a major milestone for Acticor Biotech, its collaborators, investigators, stakeholders and above all for stroke patients. These results will be presented at ESOC 2024, Europe's leading stroke research conference. We are convinced that glenzocimab is a promising drug candidate for tackling the major global medical challenge represented by stroke.”